Article

In silico study of medical decision-making for rare diseases: heterogeneity of decision-makers in a population improves overall benefit

2018-09-04

Abstract excerpt

<h4>Background: </h4> Medical decision-making is difficult when information is limited due to rareness. For example, there are two treatment options for patients affected by a rare disease with high lethality. The information about both treatment effects is unavailable or very limited. Patients are inclined to accept one of the interventions rather than waiting for death, but they are reluctant to be assigned the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 30a032dc-c358-58a0-aaa0-c67a5ce4c715
DOI: 10.7287/peerj.preprints.27170v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

In silico study of medical decision-making for rare diseases: heterogeneity of decision-makers in a population improves overall benefitDOI 10.7287/peerj.preprints.27170v1Read

Treatment recommendations based on Network Meta-Analysis: rules for risk-averse decision-makersSemantic proximity Read

Heterogeneity, Bayesian thinking, and phenotyping in critical care: A primer.Semantic proximity Read

The Call for Progress in Evidence-Based MedicineSemantic proximity Read

A Meta-Learner Framework to Estimate Individualized Treatment Effects for Survival OutcomesSemantic proximity Read

Preferences for genetic interventions for SCA and Huntington’s disease: results of a discrete choice experiment among patients.Semantic proximity Read

Answering Complex Hierarchy Questions in Network Meta-analysisSemantic proximity Read

When algorithms replace biologists: A Discrete Choice Experiment for the valuation of risk-prediction tools in Neurodegenerative DiseasesSemantic proximity Read

Information theory: a guide in the investigation of disease.Semantic proximity Read

Healthconomics: trust-based decision-making in the health context discriminates biological risk profiles in Type 1 DiabetesSemantic proximity Read

Using Artificial Intelligence to Assess Treatment-Effect Heterogeneity in Pragmatic Cardiovascular Trials: Insights from TRANSFORM-HFSemantic proximity Read

Using the Bayesian credible subgroups method to identify populations benefiting from treatment: An application to the Look AHEAD trialSemantic proximity Read

Characteristic Clustering of Thrombolytic Agent Decision-making in Acute Ischemic Stroke and Analysis of Influencing FactorsSemantic proximity Read